Skip to main content
Premium Trial:

Request an Annual Quote

EpiGenesis to Get $5 Million For Respiratory Drug Discovery

Premium

DURHAM, NC--New York investment firm Muzinich & Company arranged a private placement of $2.5 million, mostly from European institutional investors, with EpiGenesis Pharmaceuticals, a drug discovery company here focused on selective manipulation of gene expression to provide novel treatments for asthma and drug-resistant cancer. Based on the company's performance, the financing could expand to $5 million within two years.

"The company's proprietary drug discovery and target validation methods represent a leap in technology that can address many unmet medical needs," Muzinich principal Karen Giroux said.

The pharmaceutical plans to use the financing to advance development of its lead compound Epi 2010, and its technology platform for the asthmatic lung. EpiGenesis plans to form an alliance with a large multinational pharmaceutical company to complete preclinical and clinical evaluation of Epi 2010, according to President and CEO Jonathan Nyce.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.